JP7793283B2 - 局所製剤およびその使用 - Google Patents

局所製剤およびその使用

Info

Publication number
JP7793283B2
JP7793283B2 JP2018543272A JP2018543272A JP7793283B2 JP 7793283 B2 JP7793283 B2 JP 7793283B2 JP 2018543272 A JP2018543272 A JP 2018543272A JP 2018543272 A JP2018543272 A JP 2018543272A JP 7793283 B2 JP7793283 B2 JP 7793283B2
Authority
JP
Japan
Prior art keywords
alkyl
formulation
aryl
heteroaryl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018543272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018532809A (ja
JP2018532809A5 (enExample
Inventor
エル． ウエィス，シドニー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of JP2018532809A publication Critical patent/JP2018532809A/ja
Publication of JP2018532809A5 publication Critical patent/JP2018532809A5/ja
Priority to JP2022177207A priority Critical patent/JP7669326B2/ja
Application granted granted Critical
Publication of JP7793283B2 publication Critical patent/JP7793283B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018543272A 2015-11-10 2016-11-03 局所製剤およびその使用 Active JP7793283B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022177207A JP7669326B2 (ja) 2015-11-10 2022-11-04 局所製剤およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562253569P 2015-11-10 2015-11-10
US62/253,569 2015-11-10
PCT/US2016/060391 WO2017083167A1 (en) 2015-11-10 2016-11-03 Topical formulations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022177207A Division JP7669326B2 (ja) 2015-11-10 2022-11-04 局所製剤およびその使用

Publications (3)

Publication Number Publication Date
JP2018532809A JP2018532809A (ja) 2018-11-08
JP2018532809A5 JP2018532809A5 (enExample) 2019-12-12
JP7793283B2 true JP7793283B2 (ja) 2026-01-05

Family

ID=58695926

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018543272A Active JP7793283B2 (ja) 2015-11-10 2016-11-03 局所製剤およびその使用
JP2022177207A Active JP7669326B2 (ja) 2015-11-10 2022-11-04 局所製剤およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022177207A Active JP7669326B2 (ja) 2015-11-10 2022-11-04 局所製剤およびその使用

Country Status (10)

Country Link
US (3) US20190231885A1 (enExample)
EP (2) EP3373976B1 (enExample)
JP (2) JP7793283B2 (enExample)
AU (1) AU2016351588A1 (enExample)
DK (1) DK3373976T3 (enExample)
ES (1) ES2974821T3 (enExample)
FI (1) FI3373976T3 (enExample)
PL (1) PL3373976T3 (enExample)
PT (1) PT3373976T (enExample)
WO (1) WO2017083167A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2948387T3 (es) 2012-08-24 2023-09-11 Sun Pharmaceutical Ind Ltd Formulación oftálmica de ácidos grasos polioxílicos o lípidos polioxílicos y tratamiento de afecciones oculares
DK3373976T3 (da) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Topiske formuleringer og anvendelser deraf
PT3423076T (pt) * 2016-02-29 2024-07-01 Sun Pharmaceutical Ind Ltd Formulações tópicas contendo ciclosporina e respetivas utilizações
EP4387589A4 (en) * 2021-08-20 2025-09-03 Sun Pharmaceutical Ind Ltd STABLE OPHTHALMIC FORMULATION OF CYCLOSPORINE AND PROCESS FOR ITS MANUFACTURE

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007126110A1 (ja) 2006-04-24 2007-11-08 Nanocarrier Co., Ltd. 低分子薬物内包ポリマーミセルの製造方法
WO2007136134A1 (ja) 2006-05-23 2007-11-29 Nanocarrier Co., Ltd. 疎水性薬物内包ポリマーミセルの製造方法
WO2008010341A1 (fr) 2006-07-18 2008-01-24 Nanocarrier Co., Ltd. Polypeptide physiologiquement actif, micelle de polymère ayant une protéine enfermée dans celle-ci, et procédé d'obtention de la micelle de polymère
WO2014032026A1 (en) 2012-08-24 2014-02-27 Mitra Ashim K Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG45449A1 (en) 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
NZ247516A (en) 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5484597A (en) * 1993-07-30 1996-01-16 Chesebrough-Pond's Usa Co. Clear hydroalcholic cosmetic microemulsions
NZ280689A (en) 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
US7678836B2 (en) 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
ATE504557T1 (de) 2000-02-16 2011-04-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
US20030176356A1 (en) 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
PT1435910E (pt) 2001-10-19 2009-09-07 Isotechnika Inc Novos pré-concentrados de microemulsão de análogos da ciclosporina
AU2002365167A1 (en) 2001-12-18 2003-07-09 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
ES2527753T3 (es) 2002-04-01 2015-01-29 University Of Southern California Eicosanoides trihidroxi poliinsaturados
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
JP4845378B2 (ja) 2002-08-12 2011-12-28 ザ ブライハム アンド ウイメンズ ホスピタル，インコーポレイテッド レソルビン：治療処置用のバイオテンプレート
WO2004069181A2 (en) 2003-02-03 2004-08-19 Pharmacia Corporation Composition for the treatment of intraocular pressure
JP2004238346A (ja) 2003-02-07 2004-08-26 Shiono Chemical Co Ltd トラニラストの安定な水溶液製剤
WO2004078143A2 (en) 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
AU2003228126A1 (en) 2003-05-02 2004-11-23 Arturo Jimenez Bayardo Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US20050238589A1 (en) 2004-04-14 2005-10-27 Van Dyke Thomas E Methods and compositions for preventing or treating periodontal diseases
ES2314354T3 (es) 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
EA010802B1 (ru) 2004-11-19 2008-12-30 Мартек Байосайенсиз Корпорейшн Оксилипины из полиненасыщенных жирных кислот с длинной цепью и способы их получения и применения
US20090209599A1 (en) 2005-06-09 2009-08-20 Yoko Endo Eye drop containing roflumilast
AU2006259261B2 (en) 2005-06-16 2013-06-13 Myrexis, Inc. Pharmaceutical compositions and use thereof
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
CA2615990A1 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
EP1983977A4 (en) 2006-01-31 2011-11-30 Martek Biosciences Corp OXYLIPINES FROM STEARIDONIC ACID AND GAMMA-LINOLIC ACID AND METHOD FOR THE PRODUCTION AND USE THEREOF
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
US20110190389A1 (en) 2007-02-20 2011-08-04 Linda Arterburn Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
US20100310462A1 (en) 2007-04-18 2010-12-09 Biochromix Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
US8512687B2 (en) 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
WO2009028674A1 (ja) 2007-08-29 2009-03-05 Wakamoto Pharmaceutical Co., Ltd. ラタノプロスト含有水性医薬組成物
MX2007011165A (es) 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
AU2008310956B2 (en) 2007-10-08 2014-08-07 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US20090286718A1 (en) 2008-01-04 2009-11-19 Sirion Therapeutics, Inc. Stable Aqueous Cyclosporin Compositions
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
US20090298956A1 (en) 2008-05-28 2009-12-03 Chowhan Masood A Self-preserved emulsions
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2437756A2 (en) 2009-06-02 2012-04-11 Wu, Nian Pure peg-lipid conjugates
MX338355B (es) 2009-06-09 2016-04-13 Aurinia Pharmaceuticals Inc Sistemas de suministro de farmaco topico para uso oftalmico.
RU2012115103A (ru) 2009-09-17 2013-10-27 Сэндзю Фармасьютикал Ко., Лтд. Водные глазные капли, содержащие латанопрост, и способ ингибирования адсорбции латанопроста полимером
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
CA2798923A1 (en) 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd. Novel ophthalmic compositions
WO2013025696A1 (en) 2011-08-15 2013-02-21 Teva Pharmaceutical Industries Ltd. Ophthalmic formulations and processes for their preparation
US9278132B2 (en) 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
KR101211902B1 (ko) 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
EP2846769A1 (en) 2012-05-11 2015-03-18 Cipla Limited Pharmaceutical composition
US10946076B2 (en) 2013-02-13 2021-03-16 The Research Foundation For The State University Of New York Glaucoma treatment
MX2016015211A (es) 2014-05-23 2017-06-20 Ocular Tech Sarl Formulaciones topicas y usos de las mismas.
US20150352176A1 (en) 2014-06-06 2015-12-10 Newport Research, Inc. Oil-free and fat-free aqueous suspensions of cyclosporin
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US20180133217A1 (en) 2015-05-04 2018-05-17 Ocular Technologies Sarl Topical formulations and uses thereof
DK3373976T3 (da) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Topiske formuleringer og anvendelser deraf
EP3373924A4 (en) 2015-11-12 2019-06-19 Sun Pharma Global FZE Topical formulations and uses thereof
PT3423076T (pt) 2016-02-29 2024-07-01 Sun Pharmaceutical Ind Ltd Formulações tópicas contendo ciclosporina e respetivas utilizações
WO2017152129A2 (en) 2016-03-03 2017-09-08 Ocular Technologies Sarl Treatment of glaucoma and/or retinal diseases and formulations useful therefore

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007126110A1 (ja) 2006-04-24 2007-11-08 Nanocarrier Co., Ltd. 低分子薬物内包ポリマーミセルの製造方法
WO2007136134A1 (ja) 2006-05-23 2007-11-29 Nanocarrier Co., Ltd. 疎水性薬物内包ポリマーミセルの製造方法
WO2008010341A1 (fr) 2006-07-18 2008-01-24 Nanocarrier Co., Ltd. Polypeptide physiologiquement actif, micelle de polymère ayant une protéine enfermée dans celle-ci, et procédé d'obtention de la micelle de polymère
WO2014032026A1 (en) 2012-08-24 2014-02-27 Mitra Ashim K Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
US20150165048A1 (en) 2012-08-24 2015-06-18 Ocular Technologies Sarl Topical formulations and uses thereof

Also Published As

Publication number Publication date
ES2974821T3 (es) 2024-07-01
JP7669326B2 (ja) 2025-04-28
EP3373976A1 (en) 2018-09-19
WO2017083167A1 (en) 2017-05-18
EP4364810A3 (en) 2024-07-24
JP2018532809A (ja) 2018-11-08
PT3373976T (pt) 2024-04-02
EP4364810A2 (en) 2024-05-08
EP3373976A4 (en) 2019-05-22
AU2016351588A1 (en) 2018-05-24
US20240358840A1 (en) 2024-10-31
FI3373976T3 (fi) 2024-03-25
PL3373976T3 (pl) 2024-06-24
US20210268114A1 (en) 2021-09-02
JP2023012533A (ja) 2023-01-25
EP3373976B1 (en) 2024-01-03
US20190231885A1 (en) 2019-08-01
US12053528B2 (en) 2024-08-06
DK3373976T3 (da) 2024-04-02

Similar Documents

Publication Publication Date Title
CA2914472C (en) Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
JP7669326B2 (ja) 局所製剤およびその使用
JP7547411B2 (ja) 局所用シクロスポリン含有製剤およびその使用
US20200009137A1 (en) Topical formulations and uses thereof
WO2017083410A1 (en) Topical formulations and uses thereof
JP2018532809A5 (enExample)
WO2017152129A2 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore
HK40111394A (en) Topical formulations and uses thereof
HK40097708A (en) Topical formulations and uses thereof
HK1260924A1 (en) Topical formulations and uses thereof
HK1260924B (en) Topical formulations and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200923

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20200925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210113

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210420

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210817

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220516

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220705

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221104

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221104

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221114

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221115

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221202

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250528

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250823

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251217

R150 Certificate of patent or registration of utility model

Ref document number: 7793283

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150